Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stomach cancer combo study halted early

NCT ID NCT05251948

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested several drug combinations in 40 people with advanced stomach or gastroesophageal junction cancer that had not been treated before. The goal was to see which combinations shrank tumors. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

40 people

The number who actually took part.

Started

Mar 2022

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for Stage 1: * ECOG Performance Status of 0 or 1 * Inoperable locally advanced, metastatic, or advanced GC or GEJC, with adenocarcinoma confirmed as the predominant histology * No prior systemic treatment for advanced or metastatic disease * Life expectancy \>= 3 months, as determined by the investigator * Human epidermal growth factor receptor 2 (HER2)-negative tumors * Measurable disease according to RECIST v1.1 * Adequate hematologic and end-organ function * Patients without hepatitis B virus (HBV) infection at screening * Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening * Negative HIV test at screening * For women of childbearing potential: agreement to remain abstinent or use contraception, and agreement to refrain from donating eggs, as outlined for each specific treatment arm * For men: agreement to remain abstinent or use contraception, and agreement to refrain from donating sperm, as outlined for each specific treatment arm Exclusion Criteria for Stage 1: * Prior treatment with CD137 agonists or immune checkpoint blockade therapies * Treatment with investigational therapy within 28 days prior to initiation of study treatment * Any contraindications to any of the study drugs of the chemotherapy regimen * Eligible only for the control arm * Patients with a signet ring cells dominant carcinoma * Symptomatic, untreated, or actively progressing CNS metastases * History of leptomeningeal disease * Active or history of autoimmune disease or immune deficiency * Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina * History of malignancy other than GC or GEJC within 2 years prior to initiation of study treatment, with the exception of malignancies with a negligible risk of metastasis or death Exclusion Criteria for Tiragolumab-Containing Arm: * Prior treatment with an anti-TIGIT agent * Active Epstein-Barr virus (EBV) infection or known or suspected chronic active EBV infection at screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced gastric carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric carcinoma gastroesophageal cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric and gastroesophageal junction carcinoma

Contacts and locations

Locations

  • Affiliated Hopsital of Jining Medical University

    Jining, 272000, China

  • First Affiliated Hospital of Gannan Medical University

    Ganzhou, 341000, China

  • Nan Tong Tumor Hospital

    Nantong, 226361, China

  • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

    Nanjing, 210008, China

  • Shanxi Province Cancer Hospital

    Taiyuan, 030013, China

  • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

    Hangzhou, 310016, China

  • The First Affiliated Hospital of Xian Jiao Tong University

    Xi'an, 710061, China

  • The First Affiliated Hospital, Zhejiang University

    Hangzhou, 310003, China

  • The General Hospital of People?s Liberation Army (301 Hospital)

    Beijing, 100853, China

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, 230601, China

  • the First Hospital of Jilin University

    Changchun, 130021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.